Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioAtla, a US-China Biotech, Announces $45 Million Capital Funding

publication date: Jan 10, 2016
BioAtla LLC, a San Diego-Beijing biotech, raised $45 million from the Global BIO Impact Fund, a US bioscience investor. BioAtla will use the capital to develop its portfolio of Conditionally Active Biologic antibody therapeutics. The capital will consist of two tranches: a $15 million equity investment available at the end of January, and $30 million, available before the end of March, of non-dilutive funding to support early development of several BioAtla CAB antibody candidates. BioAtla will choose the supported programs, and Global Bio will share in the risk and/or reward of the first four BioAtla drug candidates to receive IND approval by the US FDA. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital